

TEVANIAN AVADIS  
Form 4  
February 08, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**TEVANIAN AVADIS**

(Last) (First) (Middle)

**C/O DOLBY LABORATORIES, INC., 1275 MARKET STREET**

(Street)

**SAN FRANCISCO, CA 94103**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**Dolby Laboratories, Inc. [DLB]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**02/06/2018**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |           |   |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|-----------|---|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |           |   |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |   |           |   |   |
| Class A Common Stock            | 02/06/2018                           |  | A                              |   | 3,920   | (1)  | \$ 0  | 3,920 (2) | D |   |
| Class A Common Stock            | 02/06/2018                           |  | S                              |   | 800   | D  | \$ 61.5963 (3)  | 46,607    | I | By Avadis Tevanian Jr. and Nancy Tevanian Trust u/a/d May 29 1996 |
|                                 | 02/06/2018                           |  | S                              |   | 1,817   | D  |   | 44,790    | I |   |

Edgar Filing: TEVANIAN AVADIS - Form 4

|                            |                             |  |
|----------------------------|-----------------------------|--|
| Class A<br>Common<br>Stock | \$<br>62.2272<br><u>(4)</u> | By Avadis<br>Tevanian<br>Jr. and<br>Nancy<br>Tevanian<br>Trust<br>u/a/d May<br>29 1996 |
|----------------------------|-----------------------------|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Bene<br>Own<br>Follo<br>Repo<br>Trans<br>(Instr |
|---|--|---|---|--------------------------------------|--|--|---|---|--|
|   |  |   |   | Code                                 | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares                                     |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |              |         |       |
|--|---------------|--------------|---------|-------|
|  | Director      | 10%<br>Owner | Officer | Other |
| TEVANIAN AVADIS<br>C/O DOLBY LABORATORIES, INC.<br>1275 MARKET STREET<br>SAN FRANCISCO, CA 94103 | X             |              |         |       |

## Signatures

/s/ Daniel Rodriguez, as Attorney-in-Fact for Avadis  
Tevanian

02/08/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Award represents a total of 3,920 restricted stock units granted under the terms of the Issuer's 2005 Stock Plan. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting, which will occur on the earlier of (i) the first anniversary of the date of grant or (ii) the date immediately preceding the date of Issuer's 2019 annual meeting of stockholders, provided that, in either case, the Reporting Person continues to serve as a member of the Issuer's board of directors on such date.

(2) Shares held following the reported transactions include 3,920 restricted stock units, which are subject to forfeiture until they vest.

(3) This transaction was executed in multiple trades at prices ranging from \$60.94 to \$61.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

(4) This transaction was executed in multiple trades at prices ranging from \$61.96 to \$62.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

### Remarks:

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.